New Zealand: Strategic Tips For Adding Value To Licensing Transactions

Last Updated: 18 November 2008


A licence is permission to do something that would, in the absence of permission, infringe intellectual property rights. It is different to an assignment, which is a transfer of ownership of the intellectual property.

Using a house as an analogy for the intellectual property, renting the house is like granting an exclusive licence, while selling the house would be an assignment.

All forms of IP can be licensed, including patents, trade secrets (know-how), copyright, trade marks, designs and plant variety rights. The rewards obtained by the licensor for the grant of rights can include an upfront payment, ongoing royalties, milestone payments, equity, services, R&D funding and access to improvements.

The desirability of a licence arrangement has to be considered from two perspectives, that of the potential licensee ("licensing-in") and of the potential licensor ("licensing-out").

Licensing-in is an appropriate strategy when a protected technology could provide a significant competitive advantage, and it is either impossible to design around the protection, and/or it is more cost effective to pay a royalty for use of the technology than to create it from scratch or design around the protection.

Licensing-out is an effective strategy in circumstances where giving third parties access to the technology in return for a fee will generate greater revenue for the same or less risk as not granting access. For example, granting rights in foreign territories or in relation to non-core applications for the technology.

This paper focuses on licensing effectively to maximise value from the licensing-out perspective.

Reduce risk for licensee

The negotiation of a licence is essentially the allocation of risk and reward between the licensee and licensor. The more risk taken on by the licensee, the greater its portion of the reward from the innovation should be. This fundamental tenet should be remembered when a licensor is first seeking a licensee. The more risk the licensor can take out of the equation, the easier it will be to find a licensee and the better the licence terms will be for the licensor.

The types of risk that are involved in commercialisation of IP include:

  • R & D risk – is there proof of principle, will the product pass the regulatory hurdles?
  • Manufacturability risk – can the invention be scaled up for commercial production, can it be manufactured for a competitive price?
  • Marketing risk – do consumers want or need the end product, is there a suitable distribution channel?
  • Competitive risk – how will competitors react to the introduction of the end product, will it be superseded quickly by new technology?
  • Legal risk – can it be sold without infringing third party rights?

Accordingly, if the innovation is a mere idea without proof of principle, then the licence is a very risky proposition for the licensee. With proof of principle, there is less risk, and a working prototype will remove even further risk. If the licensor can demonstrate sales, then again, it has reduced the risk from the licensee's perspective.

With this in mind, the licensor must make a decision as to when will be best to licence the IP. Net present value calculations based on revenue forecasts for each scenario can be conducted to determine the optimum point at which to begin licensing.

For example, in a study of pharmaceutical companies' licensing practices, Kalamus, Pinkus and Sachs argue that big pharma would "capture the greatest expected value from preclinical licensing virtually 100 percent of the time because the greater risk of failure for preclinical compounds was more than offset by the low terms available early on" ("The new math for drug licensing", McKinsey Quarterly, 2002 No. 4). The authors went on to argue that the current reluctance of biotech companies to accept these low terms could be addressed by big pharma paying more for preclinical deals, stating "in most cases, they could pay 150 percent more at the preclinical stage for the rights to a drug" and still come out ahead, on the basis that they would take more bets earlier, creating a diversified portfolio out of which one or two compounds would generate super normal profits.

Carve up rights and select appropriate licensees

A licence does not have to cover all the rights enjoyed by the IP owner. The owner may licence the right to market products but not manufacture them for example, or market products in a particular country or for particular uses but not others. In this way, each exclusive right of the IP owner (for example, if we are talking about patent rights relating to a new vaccine, to make, use, exercise and vend) can be sliced and diced according to field of use (eg animal not human), region (Europe not the rest of the world), vertical markets (to wholesalers not retailers) and horizontal markets (over the counter not prescription).

In this way, each "slice" of rights can be granted to the most suitable company in the circumstances. This process of "picking horses for courses" should mean better licensee performance in each region/application/market and therefore greater return to the licensor.

Potential licensees can be located through industry knowledge, IP searching, internet searching or broker services. Investigations can be conducted into each potential licensee in terms of their financial position, previous or existing licence relationships and cultural and technological fit of the licensed product.

If a product or process has or may have more than one potential use/application, the licensor should only grant rights to the licensee in respect of the uses/applications in which the licensee can demonstrate the necessary experience and competence.

Even if the licensor believes there is only one use/application for the product or process, the licence should be drafted to grant rights to that particular use/application. There have been numerous examples in history of a product that was first thought to have only one use actually performing better in another application. The licensor wants to avoid inadvertently granting rights to these undiscovered applications, which in the long term may be even more valuable than the known application.

Very few companies truly have manufacturing and marketing capabilities in all countries of the world. A licensor should avoid granting worldwide rights unless the licensee is one of these multinational companies.

While there is always a temptation to do one mega-deal for the entire world, this may not be the best approach. Picking the best possible licensee for each region of the world will usually result in the maximum return to the licensor, even though it involves more negotiation and deal making and relationships with multiple licensees.

If the extent of the territory is an issue for the licensee, the licensor could consider a number of alternatives to give the licensee some concession while minimising the licensor's exposure to risk of poor performance:

  • Grant worldwide rights (or a large territory) but include the ability to terminate the rights on a country by country basis in the event there is no or insufficient activity in the country after a certain period of time.
  • Grant rights to a limited territory, but grant a right of first refusal to additional territories.
  • Impose minimum royalties on a country by country or region by region basis.
  • Charge upfront fees on a country by country basis.

Getting upfront payments

A licensor will often require a lump sum initial payment (or sign-on fee) as part of the consideration for the licence. Degnan and Horton indicate that 60% of licences have upfront fees (Degnan, S. and Horton, C. "A Survey of Licensed Royalties" les Nouvelles June 1997).

The payment is designed to create immediate commitment to the relationship on the part of the licensee. The money is useful to the licensor as it may provide funds for further IP protection, or represent recovery of a portion of R&D costs. For the licensee, the upfront payment represents the sum most at risk.

Generally, the higher the upfront payment the lower the ongoing royalty.

One author suggests that the upfront fee should be about 15% of the "modified replacement cost" of the technology (Betten, P. "Valuing Upfront License Fees" les Nouvelles March 2000). The modified replacement cost is based on the time, materials and equipment the inventor would need (knowing what he/she now knows about the invention) to rediscover or create the technology, with an adjustment depending upon how easy it would be for an independent person to invent around the technology.

Other approaches to upfront payment calculations include:

  • List pricing – a figure (usually per licensed patent) set to recover the patent, administrative and licensing costs associated with the transaction
  • 10% of peak sales – a figure based on 10% of the forecasted peak product sales
  • Net present value of peak forecasted royalties
  • 25% of peak forecasted royalties.

If the licensee is unwilling to pay a significant upfront fee, and the licensor requires funds in the short term, consider using a sign-on fee that is credited against the licensee's royalty account (i.e. prepaid royalties). The licensor should be careful to provide that the sum is non-refundable, even if actual royalties do not use up the entire credit. Alternatively, payments of a sign-on fee could be staged over time, or milestone payments linked to significant events, such as regulatory approvals or hitting certain sales points, could be used.

Alternatively, the licensor could adjust other clauses in the agreement to relieve some of the financial burden on the licensor – such as making the licensee pay for filing, prosecution, maintenance and/or enforcement of IP rights, or increasing the minimum royalty payments.

Negotiating royalties

Royalty base

The key definition in the royalty provisions is not the size of the royalty rate, but the base to which the royalty rate is applied. Should the royalty be a percentage of the invoiced sale price of the product, the manufactured cost or profit margin? Should the royalty be a piece rate – that is a set figure per product sold or manufactured?

If possible, avoid profit as a royalty base, because profit figures can be manipulated by skilful accounting. It is much harder to manipulate the sale price. When defining what constitutes a royalty bearing sale, consider using terminology familiar to accountants, as it is usually accountants who will calculate the royalty payments, and conduct audits on behalf of the licensor.

Give consideration to other means of disposing of the product, such as by lease, hire, gift, internal use and such like. Also consider how transfers between related companies will be dealt with.

Piece rates are easy to calculate, although over time can become eroded by inflation. Accordingly, if a piece rate is used, then an inflation adjustment provision should be included.

Royalties for processes can be based on throughput, time used, or degree of cost saving (e.g. output of waste) and such like.

Software is often licensed for a fee, either a one off payment or a continuing payment (e.g. an annual fee), and the quantum of payment is sometimes tied to the number of users or size of the user organisation.

Royalty rate

Once the royalty base is determined, then the licensor must negotiate the royalty rate (e.g. the percentage applied to the royalty base). Determination of the royalty rate should have regard to two main factors:

  • Industry norms
  • Projected profits

Royalty rates for various groups of technologies based on established and successful licensing arrangements are of interest as a check in relation to costs within industries and the profit margins of efficiently run businesses. This benchmarking against similar products or technologies relies on the availability of sufficient public information. Where such information is not so readily available, research companies may for a fee, provide royalty information on products and industries, based on their surveys and data compiled from various sources. Royalty Source ( and Tech Agreements ( are examples of such companies, the latter charging US$35 per agreement. There are also published studies of royalty rates that can be accessed freely.

There are a number of rules of thumb which can used to find an appropriate royalty rate. One well known rule of thumb is the so-called "25% Rule" (see Goldscheider, R. Jarosz, J. and Mulhern, C. "Use of the 25 Per Cent Rule in Valuing IP" les Nouvelles December 2002). Under this rule projected profits to the licensee are the starting point, with the core assumption being that the innovator should be entitled to approximately 25% of the gross operating return from the innovation. In addition to the cost of sales, some proponents of the rule advocate deducting non-manufacturing operating expenses. The operating profit to be used should be pre-interest and tax.



Cost of sales


Gross Margin


Operating expenses


Operating profits


Royalty rate

5% ($20*25%/100)

The application of the 25% rule will in most instances give an unrealistically high figure and other factors may be taken into account to adjust the royalty rate downwards.

Adjustments to a royalty established under the 25% rule should be made having regard to factors such as:

  • Licensee competencies resulting in low cost of sales relative to competition
  • Strength and breadth of the IP protection
  • Availability of viable substitutes.

Other factors that impact upon the setting of royalty rates include:

  • Territorial extent of rights
  • Exclusivity of rights
  • Level of innovation
  • Degree of competition in the relevant markets
  • Strategic need or portfolio fit
  • Stage of development
  • Royalty stacking issues
  • Other reward/compensation elements in the deal structure (eg research services, equity, milestones, etc).

Other royalty issues

Where a licensed product is the subject of patent rights, copyright protection and trade mark protection, the licensee should consider apportioning the total royalty rate between these various forms of protection. In this manner, if a patent lapses or is invalidated, there is less likely to be a dispute as to whether the agreement should be renegotiated or terminated. It may also make accounting for tax easier as different tax rules can apply to different IP types.

In a similar vein, the parties could provide for a step-down in the patent royalties in the event the patent is subjected to a challenge which indicates it may be invalid (but, for example the challenge is settled before the patent is actually revoked).

There may be issues where a product is protected by patent claims in some regions of the licensed territory but not in others. The licensee may refuse to pay a royalty in non-patent protected countries (unless there is some valuable know how that forms part of the licence). However, there are possible justifications for paying a royalty across the board regardless of the patent position in individual countries. For example, the licensee will develop know how in the course of manufacturing and selling the patent territories that will be applied in non-patent territories, it benefits from the significant R&D expenditure of the licensor relating to the product in all countries (without the licence it would have to incur this expense itself) and so on.

Where there is a differential royalty rate depending on the protection in a country, care has to be taken that the licensee cannot make and sell product in a low royalty rate country and then have the purchaser resell into a high royalty rate country without paying the differential.

A licensee may legitimately argue that it has to bring a number of technologies from different licensors together to create the final product, and that there is a ceiling total royalty payable on the final product beyond which it is no longer economically viable to sell. In these royalty stacking situations, the licensee may negotiate an adjustment mechanism for the royalty rates in existing agreements, where a new licence required pushes the total royalty rate over the ceiling rate.

Where products are bundled together and sold as a single unit (A joined with royalty bearing B to form AB), there is the potential for either the licensee's accounting system to fail to recognise the sale of AB as the sale of a royalty bearing B, or for the licensee to code it as a sale of A and a free B, thereby avoiding a royalty (unless the definition of "sale" is made to include using or transferring title to B). Some definitions of "net sales" will specifically exclude products given away in the course of a promotion.

Similarly, where a royalty bearing product is provided as part of a service, there may be potential for the licensee to charge little for the product and give the service the bulk of the price weighting, thereby minimising any royalty due.

There may be issues where the licensee argues some royalty bearing stock has become obsolete and is scrapped or written off.

The royalty clause should be drafted carefully so as to properly capture sales made by a sublicensee (if sublicensing is permitted).

Finally, where substantial royalties are expected and the royalty is paid relatively infrequently (eg quarterly), then consideration should be given to securing the royalty payment using a general security agreement which is registered (in New Zealand) under the Personal Property Securities Register. In other countries a debenture or charge may be used.

Other licence consideration

Milestone payments

Milestone payments reflect the diminishing risk associated with the licence and reward the licensor for success of the technology. Typical events used to trigger a milestone payment include:

  • Filing a patent
  • Grant of a patent
  • Completion of clinical trials (pharma) or other testing (eg beta testing of software)
  • Grant of regulatory approval
  • Product launch
  • Sales thresholds

Equity investment

Upfront fees and milestone payments are sometimes taken in the form of equity investment. Equity can give the licensor some control in relation to the technology commercialisation, and may result in a closer relationship between the licence partners. As the licensor will benefit from increased profits of the licensee in the form of dividends and/or capital appreciation, the provision of equity may also facilitate a lower ongoing royalty rate.


When licensing intellectual property, the value of the transaction to the licensor is affected dramatically by the future performance of the licensee. Strategies to mitigate this risk include careful selection of licensees, carving up the licensable property and granting rights to areas in which licensees have proven track records. Careful use of royalty and payment provisions, performance obligations and other incentives will also maximise the value of the transaction.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.